Why Ocera Therapeutics (OCRX) Stock Is Plunging Today

NEW YORK (TheStreet) -- Ocera Therapeutics  (OCRX) plunged Thursday after the company priced its secondary offering of 4.2 million shares of common stock at $6 a share.

The offering will raise gross proceeds of $25.2 million before deduction of the underwriting discount and other offering expenses, Ocera said in a statement. The offering includes a 30-day option for underwriters to purchase up to 630,000 additional shares of common stock, which would result in additional gross proceeds of $3.78 million if fully exercised.

The stock was down 16.69% to $5.94 at 3:38 p.m. More than 1.1 million shares changed hands, which dwarfed the average volume of 46,163.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Ocera (OCRX) Stock Rises on Positive Drug Trial Results

5 Stocks Under $10 Set to Soar

Insider Trading Alert - SWHC, MTSI And OCRX Traded By Insiders

Insider Trading Alert - DXCM, FDP And OCRX Traded By Insiders